These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 26434876)

  • 1. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
    Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.
    Jiang JT; Wu CP; Deng HF; Lu MY; Wu J; Zhang HY; Sun WH; Ji M
    World J Gastroenterol; 2004 Jun; 10(11):1675-7. PubMed ID: 15162550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
    Ng WW; Tong KJ; Tam TN; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer.
    Banfi G; Bravi S; Ardemagni A; Zerbi A
    Int J Biol Markers; 1996; 11(2):77-81. PubMed ID: 8776607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
    Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T
    Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
    Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
    Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
    Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
    J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer.
    Banfi G; Zerbi A; Pastori S; Parolini D; Di Carlo V; Bonini P
    Clin Chem; 1993 Mar; 39(3):420-3. PubMed ID: 8448851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers].
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):741-4. PubMed ID: 16255879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.
    Nilsson O; Johansson C; Glimelius B; Persson B; Nørgaard-Pedersen B; Andrén-Sandberg A; Lindholm L
    Br J Cancer; 1992 Feb; 65(2):215-21. PubMed ID: 1739620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
    Yamao T; Kai S; Kazami A; Koizumi K; Handa T; Takemoto N; Maruyama M
    Jpn J Clin Oncol; 1999 Nov; 29(11):550-5. PubMed ID: 10678558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.
    Louhimo J; Alfthan H; Stenman UH; Haglund C
    Oncology; 2004; 66(2):126-31. PubMed ID: 15138364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) values in patients with pancreatic cancer or pancreatitis].
    Changchine CS; Yung CY; Tzen KY
    Changgeng Yi Xue Za Zhi; 1991 Mar; 14(1):32-8. PubMed ID: 2039968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the value of combined detection of tumor markers CA724, carcinoembryonic antigen, CA242, and CA19-9 in gastric cancer.
    Zhou CM; Zhao SH
    World J Gastrointest Oncol; 2024 May; 16(5):1737-1744. PubMed ID: 38764828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.